IntriCon Corporation (NASDAQ: IIN), a designer, developer, manufacturer and distributor of body-worn medical and electronics devices, will unveil its Scenic™ DSP amplifier at AudiologyNOW!, the annual convention of the American Academy of Audiology, being held April 14-17, 2010, at the San Diego Convention Center.
“This is an opportunity for hearing aid manufacturers to experience firsthand how the latest in DSP technology can help people suffering from hearing loss. Scenic is the direct result of our sustained focus on research and development.”
"We're very excited to release our high-performance Scenic amplifier at the audiology industry's largest annual event," said Mark Gorder, chief executive officer of IntriCon. "This is an opportunity for hearing aid manufacturers to experience firsthand how the latest in DSP technology can help people suffering from hearing loss. Scenic is the direct result of our sustained focus on research and development."
IntriCon's Scenic DSP amplifier is a high-performance hearing aid amplifier with advanced acoustic scenic analysis capabilities, including impulsive noise suppression and wind noise suppression, steady-state noise reduction and improved adaptive feedback cancellation.
AudiologyNOW! is the unparalleled annual event of, by and for audiologists, held by the American Academy of Audiology, the world's largest professional organization of audiologists. With an active membership of more than 11,000 audiologists, the academy promotes quality hearing and balance care by advancing the profession of audiology through leadership, advocacy, education, public awareness and support of research.
IntriCon to Launch New Corporate Web Site
IntriCon also announced that it will be launching a new corporate Web site. The redesigned www.intricon.com features intuitive, user-friendly navigation, in-depth information on the company and its capabilities and a more up-close look at IntriCon products. Users will be able to view the new site beginning April 15.
Patient-derived organoids: Transforming cancer research and personalized medicine